News
ALRN
0.1880
+5.38%
0.0096
--HC Wainwright Downgrades Aileron Therapeutics to Neutral From Buy
--HC Wainwright Downgrades Aileron Therapeutics to Neutral From Buy
MT Newswires · 08/02 05:44
Aileron slips 12% after announcing changes to breast cancer trial design
Nano-cap biotech Aileron Therapeutics (NASDAQ:ALRN) <font co...
Seekingalpha · 08/01 19:22
Sector Update: Health Care
Sector Update: Health Care
MT Newswires · 08/01 15:24
BRIEF-Aileron Therapeutics Inc Says Cash Runway Has Been Extended
BRIEF-Aileron Therapeutics Inc Says Cash Runway Has Been Extended
Reuters · 08/01 14:30
Aileron Therapeutics Changes Strategy for Phase 1b Trial of Breast Cancer Drug ALRN-6924; Shares Fall
Aileron Therapeutics Changes Strategy for Phase 1b Trial of Breast Cancer Drug ALRN-6924; Shares Fall
MT Newswires · 08/01 13:48
--Jones Trading Downgrades Aileron Therapeutics to Neutral from Buy
--Jones Trading Downgrades Aileron Therapeutics to Neutral from Buy
MT Newswires · 08/01 12:28
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 08/01 12:16
Aileron Therapeutics Outlines Strategy To Strengthen Phase 1b Clinical Trial Of ALRN-6924 In Patients With p53-Mutated Breast Cancer
  Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mut...
Benzinga · 08/01 11:52
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mutat...
GlobeNewswire · 08/01 11:51
Aileron Therapeutics Chief Medical Officer Leaves
MT Newswires · 07/08 16:48
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph....
GlobeNewswire · 07/08 12:31
--HC Wainwright Adjusts Price Target on Aileron Therapeutics to $1 From $2, Reiterates Buy Rating
MT Newswires · 06/30 06:28
Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting
Aileron Therapeutics (NASDAQ: ALRN) announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing treatment with first-line carboplatin plus pemetrexed with or without imm...
Benzinga · 06/29 13:46
Aileron drug fails to beat placebo in reducing chemo toxicities in lung cancer patients in trial
Aileron Therapeutics (NASDAQ:ALRN) <a href="https://seekinga...
Seekingalpha · 06/29 11:30
BRIEF-Aileron Therapeutics Announces Interim Data From Phase 1B Chemoprotection Trial Of Alrn-6924 In Patients With P53-Mutated Non-Small Cell Lung Cancer (Nsclc) And Confirms Development Path For Alrn-6924 Focused On P53-Mutated Breast Cancer
BRIEF-Aileron Therapeutics Announces Interim Data From Phase 1B Chemoprotection Trial Of Alrn-6924 In Patients With P53-Mutated Non-Small Cell Lung Cancer (Nsclc) And Confirms Development Path For Alrn-6924 Focused On P53-Mutated Breast Cancer
Reuters · 06/29 10:46
Aileron Therapeutics Announced Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced interim data from its Phase 1b chemoprotection trial of patients with ...
Benzinga · 06/29 10:32
--Ladenburg Thalmann Initiates Coverage on Aileron Therapeutics With Buy Rating, $2 Price Target
MT Newswires · 06/13 09:28
BRIEF-Aileron Therapeutics Files For Mixed Shelf Of Up To $150 Million
reuters.com · 06/08 10:22
BRIEF-Aileron Therapeutics Says Board Appointed Manuel Aivado, Co's CEO To Serve As Co's Principal Financial Officer, Principal Accounting Officer
reuters.com · 06/07 12:43
Aileron begins dosing in phase 1b trial of ALRN-6924 to prevent toxicities due to chemotherapy
Aileron Therapeutics (NASDAQ:ALRN) said it treated the first patients in a phase 1b trial of ALRN-6924 to prevent chemotherapy induced toxicities. The Boston-based company is evaluating ALRN-6924 for preventing chemotherapy-induced neutropenia,
Seekingalpha · 05/19 15:52
More
Webull provides a variety of real-time ALRN stock news. You can receive the latest news about Aileron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALRN
Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. The Company is focused on developing medicines to make chemotherapy safer. ALRN-6924, is its MDM2/MDMX dual inhibitor, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focuses on treating patients with p53-mutated cancers. It is developing ALRN-6924 to selectively protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced toxicities. It stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. Its platform enables it to chemically stabilize and improve the activity of a range of alpha-helical peptides. ALRN-6924 can pause cell division in cells with wild type (WT), p53, including normal bone marrow cells, and ALRN-6924 has no activity against cancer cells with mutations in p53.